Vimarsana
Biggest News Aggregation in the World

Page 8 - David Schull News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from David Schull. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In David Schull Today - Breaking & Trending Today

ChromaCode Announces Landmark Peer-Reviewed Publication on Breakthrough HDPCR Assay for Non-Small-Cell Lung Cancer - Vimarsana News

ChromaCode Announces Landmark Peer-Reviewed Publication on Breakthrough HDPCR Assay for Non-Small-Cell Lung Cancer

/PRNewswire/ -- ChromaCode, Inc., a pioneering genomics multiplexing platform company developing accessible and affordable solutions for laboratories, patients...

BioXcel Therapeutics Provides Update on Recent Developments for Late-Stage Clinical Programs and Expansion of IP Portfolio for IGALMI™ (dexmedetomidine) Sublingual Film - Vimarsana News

BioXcel Therapeutics Provides Update on Recent Developments for Late-Stage Clinical Programs and Expansion of IP Portfolio for IGALMI™ (dexmedetomidine) Sublingual Film

Meetings scheduled with FDA in October and November for TRANQUILITY and SERENITY III programs Company strengthens IGALMI™ market exclusivity through receipt of two Notices of Allowance ...

Kintara Therapeutics Presents Case Studies of Glioblastoma Patients Treated with VAL-083 at 2023 European Association for Neuro-Oncology Annual Meeting - Vimarsana News

Kintara Therapeutics Presents Case Studies of Glioblastoma Patients Treated with VAL-083 at 2023 European Association for Neuro-Oncology Annual Meeting

SAN DIEGO, Sept. 25, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. , a biopharmaceutical company focused on the development of new solid tumor therapies, today announced the presentation of...

Kintara Therapeutics Announces Fiscal 2023 Year Financial Results and Provides Corporate Update - Vimarsana News

Kintara Therapeutics Announces Fiscal 2023 Year Financial Results and Provides Corporate Update

SAN DIEGO, Sept. 18, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. , a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results...

RG6501 (OpRegen®) Phase 1/2a Additional Results to Be Featured at 23rd EURETINA Congress - Vimarsana News

RG6501 (OpRegen®) Phase 1/2a Additional Results to Be Featured at 23rd EURETINA Congress

CARLSBAD, Calif.--(BUSINESS WIRE)--Sep 13, 2023--